The ephemeris, orbital decay, and masses of 10 eclipsing HMXBs

We take advantage of more than 10 years of monitoring of the eclipsing HMXB systems LMC X-4, Cen X-3, 4U 1700-377, 4U 1538-522, SMC X-1, IGR J18027-2016, Vela X-1, IGR J17252-3616, XTE J1855-026, and OAO 1657-415 with the ASM on-board RXTE and ISGRI on-board INTEGRAL to update their ephemeris. These results are used to refine previous measurements of the orbital period decay of all sources (where available) and provide the first accurate values of the apsidal advance in Vela X-1 and 4U 1538-522. Updated values for the masses of the neutron stars hosted in the ten HMXBs are also provided, as well as the long-term lightcurves folded on the sources best determined orbital parameters. These lightcurves reveal complex eclipse ingresses and egresses, that are understood mostly as being due to the presence of accretion wakes. The results reported in this paper constitute a database to be used for population and evolutionary studies of HMXBs, as well as theoretical modelling of long-term accretion in wind-fed X-ray binaries.Comment: Accepted for publication on A&

Late Permian paleomagnetic results from the Lodève, Le Luc, and Bas-Argens Basins (southern France): Magnetostratigraphy and geomagnetic field morphology

© 2014 Elsevier B.V. Paleomagnetic results are presented from 271 stratigraphically-ordered horizons at four locations in southern France. Our focus is mainly on the Late Permian (258 horizons), but results from 13 horizons in the Triassic Buntsandstein are also reported. We argue that the Permian results extend magnetostratigraphic coverage up to the upper Capitanian Stage, some 6 million years after the end of the Permo-Carboniferous Reversed Superchron defined by the Illawarra Reversal in the Wordian Stage. When combined with published data, an overall mean paleopole at 49°N, 161°E (A95=4°, N=9) is obtained. This is virtually identical to the upper Permian pole obtained by Bazhenov and Shatsillo (2010) using the intersecting great-circle method. Agreement between the two procedures, which are based on entirely independent data, supports the geocentric axial dipole (GAD) model

A 120-Mpc Periodicity in the Three-Dimensional Distribution of Galaxy Superclusters

Using a new compilation of available data on galaxy clusters and superclusters we present evidence for a quasiregular three-dimensional network of rich superclusters and voids, with the regions of high density separated by about 120 Mpc. We calculate the power spectrum for clusters of galaxies; it has a peak on the wavelength equal to the step of the network; the excess in the amplitude of the spectrum over that of the cold dark matter model is by a factor of 1.4. The probability that the spectrum can be formed within the framework of the standard cosmogony is very small. If the cluster distribution reflects the distribution of all matter (luminous and dark), then there must exists some hithero unknown process that produces regular structure on large scales.Comment: Tex, 6 pages, 2 PostScript figures embedded, accepted by Nature on November 19, 199

ОБҐРУНТУВАННЯ ЦІЛЬОВОГО ПРОФІЛЮ ЯКОСТІ ДЛЯ РОЗРОБКИ КОМБІНОВАНИХ ОЧНИХ КРАПЕЛЬ ДЛЯ ТЕРАПІЇ ГЛАУКОМИ

Substantiation of a QUALITY Target PROFILE FOR THE DEVELOPMENT OF COMBINED eye drops for glaucoma treatmentA.M.Yakubchuk, E.G. Fetisova, A.V.Dorovskyy, L.M. AndryukovaNationalPharmaceuticalUniversity, Kharkiv.The article contains the definition of an element of pharmaceutical development, namely, the quality target profile of combined eye drops for glaucoma treatment. The feasibility of the drug developing has been scientifically substantiated by the research results of current trends in the glaucoma treatment, one of which is a combination of drugs with different mechanisms of action.The quality target drug profile has been defined in relation to quality, safety and efficacy. It forms the basis for development planning and a better understanding of the drug and the process.Substantiation of quality target profile for combined eye drops with antyglaucomous actions has been conducted for all aspects that recommended by guidelines 42-3.0:2011 «Medicinal products. Pharmaceutical development (ICH Q8)» taking into account the characteristics of the dosage form, and set consistently: the alleged use in the clinical setting, route of administration, dosage form, delivery system; strength dose; system container / closure means; quality criteria of medicinal product designated for placing on the product market.It has been substantiated intended use in a clinical setting, route of administration and dosage form with the assistance of available scientific data, information and knowledge:- Active substance Timolol maleate - adrenergic agent, is most often used at the present date as part of hypotensive drugs; Taurine refers to the substances that stabilize adrenergic receptors and can change the pharmacological activity of adrenergic drugs;- Combined use of Timolol maleate and Taurine enhances the hypotensive effect by reducing production and increasing the outflow of aqueous humor, because of pharmacological synergy action of both drugs, which provides increased outflow of aqueous humor through the drainage system of the eye;- Eye drops continue to be the most common dosage form in ophthalmology, providing local application by instillation into the eye.Regarding potency doses: active substances selected for the development of combined eye drops are well known and used as part of eye drops (mono-drugs), their therapeutic concentrations are given in the references, and for the study selected concentration of 0.34% for timolol maleate and 4% - for taurine.Planning choice of container / closure means has been made taking into account, firstly, the market experience of primary packaging for finished mono drugs of timolol and taurine, secondly, available facilities of eye drops industrial production in various primary packaging types inUkraine. Given the number of appointed drug instillation for daily glaucoma treatment (1 drop), drops weight interval for domestic production drip (25-45 mg), and the shelf life of eye drops after opening the vial (1 month) the studies have been planned in the following types of primary packaging: glass containers with nominal capacity of 5 ml closed by rubber closures and pressurized by aluminum caps; low density polyethylene containers with a capacity of 1 ml and 5 ml made by Blow-Fill-Seal packaging system; assembly low density polyethylene containers with a capacity of 5 ml.Regarding the aspect of substantiation of the drug quality criteria: the regulated indicators and the biomedical requirements were the basis. The list of biomedical monitoring indicators consists of pH, osmolarity, viscosity, refractive index. It has been applied general list of basic requirements for eye drops drug form in aqueous solution at multidose containers that developed by us based on the analysis and evaluation of the different regulations and information sources.Key words: combined eye drops, glaucoma, quality target profile, quality indexes.Literature1. Likarsʹki zasoby. Farmatsevtychna rozrobka (ICH Q8): ST-N MOZU 42-3.0:2011. – Chastyna II: Dodatok do kerivnykh vkazivok z farmatsevtychnoyi rozrobky (ICH Topic Q 8 Dodatok do farmatsevtychnoyi rozrobky) - K. : MOZ Ukrayiny, 2011. – 33 s. – (Nastanova).2. Derzhavnyy reyestr likarsʹkykh zasobiv Ukrayiny. - [Elektronyy resurs]. - Rezhym dostupu: - http://www.drlz.kiev.ua/3. Kompendyum on-line. - [Elektronyy resurs]. - Rezhym dostupu: - http://compendium.com.ua/ 4. Rehystr lekarstvennykh sredstv Rossyy®. RLS®. - [Elektronyy resurs]. - Rezhym dostupu: - http://www.rlsnet.ru/5. Spravochnyk Vydalʹ «Lekarstvennye preparaty v Rossyy». - [Elektronyy resurs]. - Rezhym dostupu: - http://www.vidal.ru/6. Ratsyonalʹnaya farmakoterapyya v oftalʹmolohyy: Ruk. dlya praktykuyushchykh vrachey / E.A. Ehorov, V.N. Alekseev, YU.S. Astakhov, V.V. Brzhevskyy, A.F. Brovkyna y dr.; pod obshch. red. E.A. Ehorova. – M.: Lytterra, 2004. – 954 s.7. Kuroedov A.V. Perspektyvy prymenenyya kombynyrovannykh atyhlaukomnykh preparatov (obzor lyteratury) / A.V. Kuroedov // Klynycheskaya oftalʹmolohyya. – 2007. - №4. - S. 176 - 180.8. Kuroedov A.V. Ahressyya protyv prohressyy: kak my ponymaem éffektyvnostʹ kombynyrovannykh antyhlaukomnykh preparatov (obzor lyteratury) / A.V. Kuroedov // Klynycheskaya oftalʹmolohyya. – 2008. - №4. – S. 143 -145.9. Astakhov YU.S. Obshchye pryntsypy medykamentoznoho lechenyya zabolevanyy hlaz / YU.S. Astakhov, E.A. Ehorov, T.V. Stavytskaya // Klynycheskaya oftalʹmolohyya. – 2004. – №1. – S. 2-5.10. Ehorov E.A. Otdelʹnye klynyko–épydemyolohycheskye kharakterystyky hlaukomy v stranakh SNH y Hruzyy. Rezulʹtaty mnohotsentrovoho otkrytoho retrospektyvnoho yssledovanyya (chastʹ 2) / E.A.Ehorov, A.V. Kuroedov // Klynycheskaya oftalʹmolohyya. – 2012. - № 1. – S. 19- 22.11. Lombardini J.B. Effects of taurine and mitochondrial metabolic inhibitors on ATP-dependent Ca2+ uptake in synaptosomal and mitochondrial subcelluar fractions of rat retina // Neurochem. 1988. V. 51. №1. P. 200-205.12. Duffin R.M., Christensen R.E., Bcrgamini M.V. Suppresion of adrenergic adaptation in the eye with prostaglandin synthesis inhibitor//Invest. Ophthal.VisSci. 1980. V. 21. №5. P. 756-759.13. Maychuk YU.F. Taufon v lechenyy hlaznykh bolezney. Obzor lyteratury y sobstvennye nablyudenyya // Medytsynskye tekhnolohyy. Otsenka y vybor. - 2011. - N 1. - S.56-61.14. Nefëdov L.Y. Tauryn (byokhymyya, farmakolohyya y medytsynskoe prymenenye). - Hrodno , 1999. - 145s.15. Bunyn A.YA., Ermakova V.N., Babyzhaev M.A. Rezulʹtaty sochetannoho prymenenyya taufona y tymolola pry lechenyy bolʹnykh otkrytouholʹnoy hlaukomy // Vestn. oftalʹmolohyy. - 1990. - T .106, №4. - S .9 - 11.16. Ermakova V.N. Éffektyvnostʹ sochetanyya Taufona s antyadrenerhycheskymy preparatamy pry pervychnoy otkrytouholʹnoy hlaukome // Rossyyskyy oftalʹmolohycheskyy zhurnal. - 2008. - №2.- S. 12-17.17. Olah Z., Veselovsky J. Rabbit's intraocular pressure after instillation of timolol and aminoacid lysine, arginine, glycine or taurine mixture // Bratisl Lek Listy 2007. V. 108. №7. P. 283-286.18. Pat. 79245 U Ukrayina. A61K9/08; A61P27/02; A61K31/00. Likuvalʹnyy helʹ dlya ochey «Tauhelʹ» / Sokolova L.V. (UA), Berdey I.I. (UA). - № u 201213798; zayavl. 03.12.2012; opubl. 10.04.2003, Byul. № 7.19. Bestoxol (Eye Drops), World Medicine Ophthalmics - [Elektronyy resurs]. - Rezhym dostupu: - http://www.wm-ophthalmics.com/bestoxol_eye_drops.asp20. Taurine Eye Drops, Hangzhou East Pharmaceutical Co., Ltd. - [Elektronyy resurs]. - Rezhym dostupu: - http://www.ectrade.com/Auction/FreeSample/361379431/Qingru_Taurine_Eye_Drops.html 21. Taurine Eye Drops, Hubei Kangzheng Pharmaceutical Co., Ltd. [Elektronyy resurs]. - Rezhym dostupu: - http://image.made-in-china.com/2f0j00lvwQiVOhMSpF/Taurine-Eye-Drops.jpg 22. Taurine Eye Drops 0,4g/8ml, AdvaCarePharma - [Elektronyy resurs]. - Rezhym dostupu: - http://www.advacarepharma.com/en/pharmaceuticals/other-preparations/item/441-taurine-eye-drops.html 23. Ushakova L.Y. Voznyknovenye y razvytye syndroma «sukhoho hlaza» u bolʹnykh pervychnoy otkrytouholʹnoy hlaukomoy / L.Y. Ushakova, O.N. Shunkevych // Hlaukoma: teoryy, tendentsyy, tekhnolohyy. HRT/Spectralis Klub Rossyya - 2013: materyaly XI Mezhdunarodnoho konhressa.– M., 2013. – S. 260-264.24. Basal Tear Turnover and Topical Timolol in Glaucoma Patients and Healthy Controls by Fluorophotometry / Esmeralda V. M. J. Kuppens, Thorsren R. Srolwijk, Rob J. W. de Keizer et. al // Investigative Ophthalmology & Visual Science. - 1992. - Vol. 33, No. 12. – R. 3442 – 3448.25. Podder S.K. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition / S.K. Podder, V.C. Moy, V.H.L. Lee // Exp. Eye Res. – 1992. – Vol. 54, №5. – P. 747-757.26. Bioadhesion: The effect of polyacrylic acid on the ocular bioavailability of timolol / F. Thermes, A. Rozier, B. Plazonnet [et al.] // Int. J. Pharm. – 1992. - Vol.81. – R. 59–65.27. The effect of vehicle viscosity on the ocular bioavailability of L-653,328 / J. Grove , M. Durr , M.P. Quint [et al.] // Int. J. Pharm. - 1990. - Vol. 66, № 1-3. - R. 23-28. 28. Pat. 8501822 SSHA. A61K31/7028; A61R27/02; A61R29/00. Ophthalmic composition containing alginic acid or salt thereof / Matsumoto Eri, Nishina Yasuko, Haruna Kenichi, Arita Harumasa, Kita Akiko, (JP). - №13/431,002; zayavl. 27.03.2012; opubl. 6.08.2013. - 18 r. 29. Different Effects of Absorption Promoters on Corneal and Conjunctival Penetration of Ophthalmic Beta-Blockers / H. Sasaki [et al.] // Pharmaceutical Research. - 1995. - Vol. 2, №8. - R. 1146-1150.30. Zayava 20100311688 SSHA. A61K31/717; A61R27/04. Ophthalmic formulations, methods of manufacture, and methods of using same / Chapin; Matthew J., Minno George, Nice Jackie, Ousler III George W., Abelson Mark B. (USA). - №12/794315; zayavl. 4.06.2010; opubl. 9.12.2010. - 30 r.31. Pat. 8450295 SSHA. A61K 31/723; A61K 31/198; A61K 31/145. Ophthalmic composition containing xanthan gum and amino acid / Doi Koji, Aki Hiroshi (JP). - №12/767,185; zayavl. 26.04.2010; opubl. 28.05.2013. - 10 r.32. Andryukova L.M. Doslidzhennya z standartyzatsiyi farmatsevtychnoyi rozrobky likarsʹkykh preparativ u formi ochnykh krapelʹ: avtoref. dys. na zdobuttya nauk. stupenya dokt. farmats. nauk : spets. 15.00.03 «Standartyzatsiya ta orhanizatsiya vyrobnytstva likarsʹkykh zasobiv» / L.M. Andryukova. - Kharkiv, 2011. - 38 s.33. Andryukova L.M. Vyznachennya krytychnykh pokaznykiv yakosti likarsʹkoyi formy ochni krapli / L.M. Andryukova, O.H. Fetisova, O.M. Yakubchuk, S.M. Kovalenko // Upravlinnya, ekonomika ta zabezpechennya yakosti v farmatsiyi. - 2013. - № 6. - S. 4-9

Monolithic and hybrid integration of InAs/GaAs quantum dot microdisk lasers on silicon

A method of hybrid integration of quantum dot microdisk lasers with silicon wafer is proposed and realized. In addition to the possibility of combining microlasers with various silicon-based electronic and photonic devices, this makes it possible to significantly improve heat removal from the active region of the microlaser. The thermal resistance normalized to the mesa area reaches the level of about 0.002 (K/W)*cm2, which is significantly lower than the corresponding values of QD microlasers on GaAs substrate and monolithically grown on Si. As a result, the threshold current as well as current-induced shift of emission wavelength are reduced in continuous-wave regime

Валідація методик кількісного визначення ризатриптану в дослідженнях біоеквівалентності генериків за процедурою біовейвер

Topicality. Proof of bioequivalence of generic and reference drugs according to biovaser procedure based on the BCS for simplified registration provides for determination of solubility of active substance for establishing the BCS class and kinetics of its release from test drugs in three buffer media. These studies should be carried out according to developed and validated assay methods of active substance.Aim. To establish validation performance of assay methods of Rizatriptan in a complex of studies on determination of bioequivalence of Rizatriptan drugs in form of tablets 5 mg and 10 mg according to biowaiver procedure.Materials and methods. Validation was carried out for assay methods of Rizatriptan simultaneously studying pH-dependent solubility and kinetics of release of active substance from generic and reference drugs in three buffer media. The study was performed in range of 25-125 % of nominal content of Rizatriptan in test solution in accordance with requirements of SPU in three buffer media according to main validation parameters: full predictable uncertainty of analysis results, specificity, accuracy, repeatability, linearity.Results and discussion. Correspondence of validation performance to the acceptance criteria in all dissolution media was established.Conclusions. Based on results of validation, it was justified and experimentally proved that assay methods of Rizatriptan are suitable for analytical support of in vitro bioequivalence studies of MP containing Rizatriptan.Актуальность. Доказательство биоэквивалентности генерического и референтного лекарственных средств по процедуре биовейвер на основании БСК для упрощенной регистрации предусматривает определение растворимости действующего вещества для установления класса БСК и кинетики его высвобождения из лекарственных средств в трех буферных средах. Эти исследования должны проводиться по разработанным и валидированным методикам количественного определения действующего вещества.Цель данной работы заключалась в установлении валидационных характеристик методик количественного определения ризатриптана в комплексе исследований по установлению биоэквивалентности лекарственных средств ризатриптана в форме таблеток по 5 мг и 10 мг по процедуре биовейвер.                                                                                    Материалы и методы. Валидация проведена одновременно для методик количественного определения ризатриптана при исследованиях рН-зависимой растворимости и кинетики высвобождения действующего вещества из генерических и референтных лекарственных средств в трех буферных средах. Исследование выполнено в диапазоне 25-125 % от номинального содержания ризатриптана в испытуемом растворе в соответствии с требованиями ГФУ в трех буферных средах по основным валидационным характеристикам: полная прогнозируемая неопределенность результатов анализов, специфичность, правильность, сходимость, линейность.                                                                                              Результаты и их обсуждение. Установлено соответствие валидационных характеристик критериям приемлемости во всех исследуемых средах растворения.                                                                                                Выводы. По результатам проведения валидации обосновано и экспериментально доказано, что методики количественного определения ризатриптана пригодны для аналитического сопровождения исследований биоэквивалентности in vitro ЛС с ризатриптаном.Актуальність. Доведення біоеквівалентності генеричного та референтного лікарських засобів за процедурою біовейвер на підставі БСК для спрощеної реєстрації передбачає визначення розчинності діючої речовини для встановлення класу БСК та кінетики її вивільнення з досліджуваних лікарських засобів у трьох буферних середовищах. Такі дослідження повинні проводитись за розробленими і валідованими методиками кількісного визначення діючої речовини.Мета даної роботи полягала у встановленні валідаційних характеристик методик кількісного визначення ризатриптану в комплексі досліджень зі встановлення біоеквівалентності лікарських засобів ризатриптану у формі таблеток по 5 мг та 10 мг за процедурою біовейвер.Матеріали та методи. Валідація проведена одночасно для методик кількісного визначення ризатриптану при дослідженнях рН-залежної розчинності та кінетики вивільнення діючої речовини з генеричних та референтних лікарських засобів у трьох буферних середовищах. Дослідження виконано у діапазоні 25-125 % від номінального вмісту ризатриптану у випробуваному розчині відповідно до вимог ДФУ у трьох буферних середовищах за основними валідаційними характеристиками: повна прогнозована невизначеність результатів аналізу, специфічність, правильність, збіжність, лінійність.Результати та їх обговорення. Встановлена відповідність валідаційних характеристик критеріям прийнятності у всіх досліджуваних середовищах розчинення.Висновки. За результатами проведення валідації обґрунтовано і експериментально доведено, що методики кількісного визначення ризатриптану придатні для аналітичного супроводу досліджень біоеквівалентності in vitro ЛЗ з ризатриптаном

A weak lensing analysis of the Abell 383 cluster

In this paper we use deep CFHT and SUBARU $uBVRIz$ archival images of the Abell 383 cluster (z=0.187) to estimate its mass by weak lensing. To this end, we first use simulated images to check the accuracy provided by our KSB pipeline. Such simulations include both the STEP 1 and 2 simulations, and more realistic simulations of the distortion of galaxy shapes by a cluster with a Navarro-Frenk-White (NFW) profile. From such simulations we estimate the effect of noise on shear measurement and derive the correction terms. The R-band image is used to derive the mass by fitting the observed tangential shear profile with a NFW mass profile. Photometric redshifts are computed from the uBVRIz catalogs. Different methods for the foreground/background galaxy selection are implemented, namely selection by magnitude, color and photometric redshifts, and results are compared. In particular, we developed a semi-automatic algorithm to select the foreground galaxies in the color-color diagram, based on observed colors. Using color selection or photometric redshifts improves the correction of dilution from foreground galaxies: this leads to higher signals in the inner parts of the cluster. We obtain a cluster mass that is ~ 20% higher than previous estimates, and is more consistent the mass expected from X--ray data. The R-band luminosity function of the cluster is finally computed.Comment: 11 pages, 12 figures. Accepted for publication on Astronomy & Astrophysic

ДИНАМІКА ІНВАЛІДНОСТІ ХВОРИХ НА ГІПОТИРЕОЗ У ТЕРНОПІЛЬСЬКІЙ ОБЛАСТІ ЗА ПЕРІОД 2013-2015 РР

Hypothyroidism takes one of the main places in the structure of endocrine diseases. The urgency of the problem of people with disabilities due to hypothyroidism is emphasized by the growth not only of the primary but also the acquired disability.Purpose: studying the peculiarities of the dynamics of disability due to hypothyroidism in Ternopil region for 2013–2015.Materials and Methods. The medical-expert documentation of 692 patients and invalids due to hypothyroidism was researched, 474 of them – as a result of postoperative hypothyroidism and 218 – as a result of idiopathic. The analysis of ofcial statistical data of disability due to hypothyroidism of the adult working population was conducted.Results and Discussion. The dynamics of the primary disability index among patients and invalids with postoperative hypothyroidism has considerably improved. Indicators of primary disability of idiopathic hypothyroidism have a negative dynamics. In addition, the category of disabled persons I and II groups grew signicantly.Conclusions. Taking into account that the indicators of full and partial rehabilitation in idiopathic hypothyroidism remain low, the main principle of action with regard to persons with disabilities is their rehabilitation. It is recommended to introduce into the work of medical and preventive institutions a complex of rehabilitation measures, remedial treatment in rehabilitation centers and sanatorium and resort conditions.Гіпотиреоз займає одне з основних місць в структурі ендокринних захворювань. Актуальність проблеми інвалідів внаслідок гіпотиреозу підкреслюється зростанням не тільки первинної, але й набутої інвалідності.Мета. Вивчити особливості динаміки інвалідності внаслідок гіпотиреозу у Тернопільській області за 2013-2015 рр.Матеріали і методи: Досліджувалась медико-експертна документація 692 хворих та інвалідів внаслідок гіпотиреозу, з них 474 – внаслідок післяопераційного гіпотиреозу та 218 – внаслідок ідіопатичного. Проведено аналіз офіційних статистичних даних інвалідності внаслідок гіпотиреозу дорослого працездатного населення.Результати та їх обговорення: Динаміка показника первинної інвалідності серед хворих та інвалідів з післяопераційним гіпотиреозом вагомо покращилась. Показники первинної інвалідності ідіопатичного гіпотиреозу мають негативну динаміку. Крім того вагомо зросла категорія інвалідів І та ІІ груп.Висновки:Враховуючи, що показники повної та часткової реабілітації при ідіопатичному гіпотиреозі залишаються низькими, основним принципом дії щодо інвалідів є їх реабілітація. Рекомендується впровадити в роботу лікувально-профілактичних закладів комплекс реабілітаційних заходів, відновне лікування в реабілітаційних центрах і санаторно-курортних умовах

The ROSAT All-Sky Survey: a Catalog of Clusters of Galaxies in a Region of 1 Ster around the South Galactic Pole

A field of 1.013 ster in the ROSAT all-sky survey (RASS), centered on the south galactic pole (SGP), has been searched in a systematic, objective manner for clusters of galaxies. The procedure relied on a correlation of the X-ray positions and properties of ROSAT sources with the distribution of galaxies in the COSMOS digitised data base, which was obtained by scanning the plates of the UK Schmidt IIIa-J optical southern sky survey. The study used the second ROSAT survey data base (RASS-2) and included several optical observing campaigns to measure redshifts. The search, a precursor to the larger REFLEX survey of the whole southern sky, reached the detection limits of the RASS and the COSMOS data, and yielded a catalog of 186 clusters in which the lowest flux is 1.5e-12 erg/cm2/s in the 0.1-2.4 keV band. Of these 157 have measured redshifts. Using a limit of 3.0e-12 erg/cm2/s a complete subset of 112 clusters was obtained, of which 110 have measured redshifts. The spatial distribution of the X-ray clusters out to z = 0.15 shows an extension of the Local Supercluster to the Pisces-Cetus supercluster (z<~0.07), and a more distant orthogonal structure at 0.07<z<0.15.Comment: To be published in ApJ Supplements in February 2002: 53 pages: 18 figure

The Northern ROSAT All-Sky (NORAS) Galaxy Cluster Survey I: X-ray Properties of Clusters Detected as Extended X-ray Sources

In the construction of an X-ray selected sample of galaxy clusters for cosmological studies, we have assembled a sample of 495 X-ray sources found to show extended X-ray emission in the first processing of the ROSAT All-Sky Survey. The sample covers the celestial region with declination $\delta \ge 0\deg$ and galactic latitude $|b_{II}| \ge 20\deg$ and comprises sources with a count rate $\ge 0.06$ counts s$^{-1}$ and a source extent likelihood of 7. In an optical follow-up identification program we find 378 (76%) of these sources to be clusters of galaxies. ...Comment: 61 pages; ApJS in press; fixed bug in table file; also available at (better image quality) http://www.xray.mpe.mpg.de/theorie/NORAS